Close Menu


The companies will jointly develop CAR T-cell therapies designed to inhibit HPK1 gene expression, which has been shown to lead to T-cell exhaustion. 

Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.

Merck and Seattle Genetics will codevelop the antibody drug conjugate ladiratuzumab vedotin, while Merck gains ex-US commercialization rights to the HER2 inhibitor Tukysa.

The secure data platform will be advanced within a multi-year collaboration and can be used by Amita's clinical, operational, and research teams to provide precision cancer care.

HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.

Six large clinical systems will join Indivumed's global network and contribute multiomics data to the company's growing database.  

The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.

Sarah Cannon will bring its contract research organization's operational delivery services to the partnership, enabling Lyell to conduct trials of its T-cell therapies.

The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.